Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device - Université de Rennes Access content directly
Journal Articles Journal of Cardiovascular Medicine Year : 2018

Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device

Abstract

Aims - In addition to the transfemoral route, common approaches for transcatheter aortic valve implantation (TAVI) are the transapical and transaortic ones. Yet, these are associated with morbidity. The transsubclavian approach (TSA) is an alternative to minimize invasiveness. Methods - Fifteen consecutive patients underwent TAVI via TSA using the CoreValve Evolut R. The 14F delivery system without sheath was directly introduced into the artery. Results - Success was 100%; contrast volume was 99.4 ± 29.58 ml. Patients were extubated after 1.66 ± 0.89 h. Hemoglobin drop was 0.64 ± 0.28 g/dl. There were no complications. Hospital stay was 4.53 ± 1.24 days: 11 patients were discharged home, the remainder to rehabilitation. Conclusion - TSA is associated with limited morbidity, early patient mobilization, short hospitalization.
No file

Dates and versions

hal-01902638 , version 1 (23-10-2018)

Identifiers

Cite

Amedeo Anselmi, Jacques Tomasi, Francesco Giardinelli, Marc Bedossa, Sebastien Rosier, et al.. Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device. Journal of Cardiovascular Medicine, 2018, 19 (11), pp.664-668. ⟨10.2459/JCM.0000000000000706⟩. ⟨hal-01902638⟩
33 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More